Nagashima, Hayato
Sasaki, Nobunari
Amano, Sachie
Nakamura, Shigeru
Hayano, Motoshi
Tsubota, Kazuo
Funding for this research was provided by:
Wakamoto Pharmaceutical Co., Ltd.
Tsubota Laboratory, Inc.
Article History
Received: 30 September 2020
Accepted: 8 January 2021
First Online: 26 January 2021
Competing interests
: K. Tsubota reports he is CEO of Tsubota Laboratory, Inc., Tokyo, Japan, a company developing products for the treatment for presbyopia. Tsubota Laboratory provides consulting services to Wakamoto Pharmaceutical Co., Ltd. and has received research funding from Wakamoto Pharmaceutical. Tsubota Laboratory, Inc. consigns the experiment to N. Sasaki, S. Nakamura, and M. Hayano. Other authors declare no conflicts of interest associated with this manuscript.